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RINGINTERFEROMETRIC SOL-GEL 
BIO-SENSOR 
ORIGIN OF THE INVENTION 
The invention described herein was made in the perfor- 
mance of work under NASA contract, and is subject to the 
provisions of Public Law 96-517 (35 U.S.C. 0 202) in which 
the Contractor has elected not to retain title. 
BACKGROUND OF THE INVENTION 
A biosensor can be used to detect the presence of a 
specific antigen. These typically involve a sample of anti- 
bodies specific to the antigen of interest. There is a large 
class of biosensors that use immobilized antibodies on a 
surface as the sensing agent. The antibodies on the surface 
are identical and bind to a specific antigen, so that the sensor 
is specific to that particular antigen. 
The antibody-antigen binding event must be detected. The 
traditional detection scheme in antibody sensors is fluores- 
cence. In a typical sandwich assay, the immobilized anti- 
body binds to the antigen; the system is then exposed to a 
fluorophore conjugated tg the antibody, which then binds to 
the antigen. This tags the bound system upon exposure to 
light of a suitable wavelength. 
The binding event also can be detected by the change in 
refractive index ofthe surface that occurs whenever antigens 
become bound to the antibodies on the surface. Such a 
biosensor is disclosed in US. Pat. No. 5,663,790, in which 
the bound antibodies are on a surface overlying an optical 
ring resonator. The change in refnctive index shifts the 
resonant wavelength of the optical ring resonator. By sweep- 
ing the light frequency while observing the light intensity in 
the ring, the shift in resonant wavelength is observed, 
indicating a shift in refractive index and the corresponding 
event of the binding of the antigens to the antibodies. 
One disadvantage of such a sensor is that the light s o w e  
must have a variable wavelength that can be swept across a 
range. A related disadvantage is that the binding event can 
only be inferred after the light source wavelength has been 
swept across the range and the optical ring resonator 
response compared across the range. Another disadvantage 
is that the coupling between the change in refractive index 
in the sample and the detected optical output is limited 
because the sample is adjacent to and not within the optical 
ring interferometer. Finally, there appears to be no way of 
enhancing sensitivity of the sensor. The problem is that a 
very dilute antigen sample may not contain a suflicient 
population of antigens to bind to more than a small fiaction 
of the bound antibodies, so that the change in refiactive 
index may be so slight that the sensor cannot detect it. 
What is needed is an optical sensor having an enhanced 
sensitivity capable of detecting extremely small changes in 
refractive index so as to be capable of sensing and measuring 
extremely weak or dilute antigen samples. Moreover, what 
is needed is a sensor that does not require expensive optical 
features such as a variable wavelength light source, and 
which does not require sweeping the light source wave- 
length across a range to make a measurement. 
SUMMARY OF THE INVENTION 
A biosensor embodying the invention includes a sensing 
volume having an anay of pores sized for immobilizing a 
first biological entity tending to bind to a second biological 
entity in such a manner as to change an index of refiaction 
2 
of the sensing volume. The biosensor further includes a ring 
interferometer, one volumetric section of the ridg interfer- 
ometer being the sensing volume, a laser for supplying light 
to the ring interferometer, and a photodetector for receiving 
The array of pores can be nanometer-sized pores. The 
array of pores may be Sol-Gel. The first biological entity 
may be an antibody and the second biological entity may be 
an antigen that binds to the antibody. Alternatively, the first 
io  biological entity may be a printed polymer and the second 
biological entity may be an antigen that binds to the printed 
polymer. Or, the first biological entity may be a first DNA or 
RNA strand and the second biological entity may be a 
second DNA or RN.4 strand that is complementary to the 
j light from the interferometer. 
15 first strand. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic diagram of a first embodiment of the 
FIG. 2 is a partial cut-away cross-sectional view qualita- 
tively depicting a Sol-Gel structure constituting the sensing 
volume in the embodiment of FIG. 1. 
FIG. 3 is a view corresponding to FIG. 2 in which 
2j antibodies are held in the nanometer-size pores of the 
Sol-Gel structure. 
FIG. 4 is a view corresponding to FIG. 3 in which some 
of the antibodies have antigens bound to them, as symbol- 
ized by the shaded pores. 
FIG. 5 is a graph illustrating the change in referactive 
index of the sensing volume in the embodiment of FIG. 1 as 
a function of analyte density (density of antibody-antigen 
bound pairs in the Sol-Gel structure of FIG. 4). 
FIG. 6 is a graph illustrating the light output intensity of 
3 j the ring interferometer of the embodimeat of FIG. 1 as a 
function of the phase shift through the sensing volume. 
FIG. 7 is a gra& illustrating the light output intensity of 
the ring interferometer as a function of analyte density. 
FIG. 8 is a perspective view of a second embodiment of 
FIG. 9 is a perspective view bf a third embodiment of the 
FIG. 10 is a perspective view of a fourth embodiment of 
20 invention. 
I 
30 
40 the invention. 
invention. 
the invention. 
45 
DETAILED DESCRIPTION OF THE 
INVENTION 
The problems described in the foregoing background 
so discussion are solved by a biosensor in which the bound 
antibodies are immobilized in a nano-porous structure, such 
as Sol-Gel, that occupies a sensing volume within one arm 
or section of an optical ring interferometer. All the light 
traveling through that arm or section must pass through the 
55 bound antibody sensing volume, i.e., the nano-porous 
matrix, and thereby becomes a phase-shifted light beam due 
to the different index of refiaction of the sensing volume. 
Another portion of the ring interferometer contains light that 
has not passed through the sensing volume, and interferes 
60 with the phase-shifted light beam. The degree of the inter- 
ference is determined by the index of refiaction of the 
sensing volume, which changes as antigens become bound 
to the immobilized antibodies in the sensing volume. The 
sensor is highly responsive in part because of the complete 
65 immersion of one portion of the ring interferometer in the 
Sol-Gel or nano-porous matrix. The sensor’s sensitivity is 
greatly enhanced because the light makes multiple passes 
US 7,O 
3 
through the ring interferometer. The intensity of the inter- 
ference pattern increases as the light circulates around the 
ring interferometer, thereby enhancing sensitivity of the 
sensor. 
One advantage is that a variable wavelength light source 
is not require and no frequency sweeping or comparison is 
required, so that the sensor is simple and its response is 
immediate. 
9,847 B1 
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density) is a function of the concentration of antigens in the 
liquid or analyte introduced to the Sol-Gel structure 200, and 
other factors. h analyte having a very high concentration of 
the targeted antigen may saturate the Sol-Gel structure 200, 
5 so that all or nearly all of the immobilized antibodies may 
become bound to antigens. An analyte having a very weak 
concentration of the targeted antigen may cause antibody- 
antigen binding by only a small proportion of the immobi- 
lized antibodies. 
~ 
Referring to FIG. 1, an optical ring interferometer 100 
includes four mirrors 102, 104, 106, 108 establishing a io The analyte may be introduced to the Sol-Gel structure 
closed path consisting of optical paths ll0,112,114,116 of 200 by flowing a liquid form of the analyte over the Sol-Gel 
the ring interferometer 100. A laser 118 produces a light structure 200. The analyte may either be the liquid itself or 
beam 120 that follows the optical paths ll0-116 by reflec- may be contained in the liquid. Unbound analyte is washed 
tion on the mirrors 102-108. The light beam 120 enters the out of the Sol-Gel structure 200, leaving only the i m o b i -  
optical path 110 through the backside of the minur 102. The 15 lized antibodies in the Sol-Gel structure 200 and any anti- 
mirror 104 may be a beam splitter which transmits a portion gens from the analyte that became bound to the immobilized 
of the light traveling along the optical path 110 to a detector antibodies. 
122 and reflects the remaining portion to the next optical Binding of antigens to the immobilized antibodies in the 
path 112. A section of the optical path 114 is immersed in a Sol-Gel structure 200 changes the refractive index of the 
sensing volume 124 consisting of a 3-dimensional array or 20 Sol-Gel structure 200 that constitutes the sensing volume 
matrix of nanometer sized pores that are sized to attract and 124. The density of antigen-antibody bound pairs in the 
immobilize antibodies of a selected type. All of the light in Sol-Gel structure 200 determines the resulting change in 
the optical path 114 passes through the sensing volume 124. refractive index. The magnitude of the change, in refractive 
The array of nanometer-sized pores constituting the sensing index resulting from the introduction of the analyte to the 
volume 124 is best formed as a Soi-Gel structure of the type 25 Sol-Gel structure is a measure of the concentration of the 
disclosed in Yamanaka et al., J.  Sol-Gel Sci. Technol. 7 ,  117 antigens in the analyte. The sensor therefore provides two 
(1996). pieces of information: (a) a detectable change in refractive 
FIG. 2 is a qualitative illustration of a Sol-Gel structure index indicates the presence of the targeted antigen type in 
200 constituting the sensing volume 124, before its pores are the analyte, while (b) the magnitude of the change in 
filled with any material. In FIG. 2, the structure consists of 30 refractive index is indicative of the concentration of the 
a 3-dimensional base 210 having many 3-dimensional pores targeted antigen in the analyte. 
220 formed within it. Each pore 220 has an average pore size Referring to FIG. 1, an "unshifted" light beam 120 from 
P. The sol-gel precursor is a liquidthat can be poured into the the laser 118 travels through the mirror 102 to the optical 
stmcture, the evaporation of the liquid leaving the sol-gel path ll0 and is transmitted by the beam splitter mirror 104 
structure. Reference is made to a periodical dedicated to this 35 to the detector 122. A phase-shifted light beam consists of 
technology, the Joumol of Sol-gel Science Technology. The the portion of the light from the optical path 110 that is 
pore size P is chosen to correspond to the size of the reflected by the beam splitter mirror 104 to the path 112, SO 
antibody to be immobilized in each pore. This size ranges that it travels through the optical paths 114,116 and 110 (in 
between a few nanometers and several hundred nanometers, that order). This light beam is phase shifted by passing 
depending upon the size of the particular antibody. The 40 through the sensing volume 124 occupying one section of 
chosen antibody is one that binds to the antigen targeted by the optical path 114. Thus, the light path l l 0  has alight beam 
the sensor. In accordance with current practice, the base 210 traveling toward the beam splitter mirror 104 consisting of 
can be formed of a material such as a silicon-based com- both the unshifted light beam and the phase shifted light 
pound which is essentially inert with respect to biological beam. 4 portion of all the light in the optical path 110 is 
materials such as antibodies and antigens, for example. The 45 transmitted by the beam splitter mirror 104 to the detector 
pore size P of the Sol-Gel is selected to attmct and bind 122, so that both the phase shifted and unshifted light beams 
individual antibodies of a particular type within the pores, so impinge on the detector 122. The phase shift imposed by the 
that P is about the size of or somewhat larger than the sensing volume 124 causes interference between the shifted 
selected antibody type, in accordance with conventional and unshifted light beams, which affects the intensity of the 
practice. FIG. 3 illustrates the Sol-Gel stnicture of FIG. 2 in 50 light sensed by the detector 122. The length of the optical 
which antibodies of a selected type have been immobilized path 110 as well as the total length of the interferometer ring 
in each pore 220. The selected antibody type determines the 110,112,114,116 are preferably integral numbers of wave- 
type of antigen targeted by the sensor. FIG. 4 illustrates the lengths of the laser 118. 
Sol-Gel structure of FIG. 2 in which the Sol-Gel structure of Referring to graph of FIG. 5, the horizontal axis corre- 
FIG. 3 has been immersed in or wetted with a fluid or analyte 5 5  sponds to the concentration, p, of the targeted antigen in the 
possibly containing the targeted antigen. analyte, while the vertical axis corresponds to the change in 
Depending upon the concentration of the targeted antigen refractive index, An (left hand vertical axis) and, equiva- 
in the analyte or fluid being tested, a certain fiaction of the lently, to the phase shift, A@ (right hand vertical axis) of the 
antibodies in the pores 220 receive and bind to antigens, as light traveling in the optical path 114 through the sensing 
indicated by the dotted pores 220a. The remaining pores 60 volume 124 containing the Sol-Gel structure 200. FIG. 5 
220b contain immobilized antibodies but without antigens qualitatively depicts the behavior in which stronger concen- 
bound to them. Thus, FIG. 4 illustrates a case in which the trations of the antigen in the analyte produce proportionately 
Sol-GeI structure has been introduced to a relatively weak larger changes in refiactive index an& hence, larger phase 
concentration of antigens so that only a portion of the shifts. Such phase shifts change the interference between the 
immobilized antibodies in the Sol-Gel structure 200 receive 65 shifted and unshifted light beams at the photodetector 122, 
and bind to antigens. The proportion of antigen-antibody producing corresponding changes in the light intensity at the 
bound pairs in the Sol-Gel structure 200 (i.e., their volume photodetector 122. Referring to the graph of FIG. 6, the 
US 7,019,847 B1 , 
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horizontal axis corresponds to the phase shift A@, while the sensing volume 824 occupies a section of the waveguide 814 
vertical axis corresponds to the light intensity, I, sensed by and consists of Sol-Gel structure 200 of FIGS. 2,3 or 4. One 
the photodetector 122. As the phase shift between the advantage of the integrated sensor of FIG. 8 is that it can be 
“shifted” and “unshifted” light beams approaches 180 highly compact, especially if the laser 818 is a semiconduc- 
degrees, the light intensity at the photodetector approaches 5 tor diode laser and the photodetector 822 is a semiconductor 
a minimum, as indicated by the graph of FIG. 6. The sensor photodiode. 
may be constructed so that the phase shift is near zero in the While the embodiments of FIGS. 1 and 8 employ a 
absence of bound antibody-antigen pairs in the sensing four-sided optical path as the ring interferometer, the number 
volume 124 and approaches 180 degrees as the concentra- of sides can be any number ranging fkom three up to any 
tion of bound antibody-antigen pairs approaches saturation 10 practical number. 
(100%). Two methods exist for modifying the index of FIG. 9 illustrates a modification of the sensor of FIG. 8 in 
refraction of the ring resonator in order to set its operating which the three waveguides sections 812,814,816 and the 
point. One method uses a polymer section of the waveguide mirrors 806,808 are replaced by a semicircular waveguide 
which can have its index ofrefiaction “written”by UV light, 910, a section of which is occupied by the sensing volume 
allowing device tuning during manufacture. Another method 15 824. 
uses a small resistive heater on a portion of the waveguide FIG. 10 illustrates an embodiment in which the ring 
to thermally tune the ring resonance point. In such imple- interferometer is implemented using a full circular 
mentations, the light intensity at the detector 122 decreases waveguide 1010 formed as a mesa structure on a substrate 
as the bound antibody-antigen concentration increases. This 1020. Light is supplied to the circular waveguide 1010 by 
effect may be quantified by obtaining different samples of 20 evanescent coupling from a linear waveguide 1030 adjacent 
the photodetector output obtained using different concentra- or tangent to the circular waveguide 1010 at a contact point 
tions of targeted antigen in different analytes. The results are 1035. The term “evanescent coupling” is defined in: Hun- 
illustrated in FIG. 7, in which the targeted antigen concen- sperger, Robert M., Integrated Optics: 272eoi-y and Echnol- 
tration p in the analyte is represented by the horizontal axis om, 1991, pp. 11C113, Springer-Verlag, New York. As 
while the light intensity, I, corresponds to the vertical axis. 25 employed in this specification, the term “evanescent cou- 
In general, an increase in targeted antigen concentration in pling” is the same as “optical tnnneling” referred to in the 
the analyte (over successive samples) causes a decrease in foregoing publication. The linear waveguide 1030 has a 
light intensity at the photodetector 122. However, other laser 1018 at one end and a photodetector 1022 at the other 
arrangements of the sensor may be made by the skilled end. The distance “a” between the laser 1018 and the contact 
worker that may reverse the behavior illustrated in FIG. 7. 30 point 1035, the distance “b” between the contact point 1035 
In either case, the change in measured intensity I at the and the photodetector 1022 and the pathlength of the circular 
photodetector may be employed as a measure of targeted waveguide are all integral multiples of the wavelength of the 
antigen concentration p in the analyte. laser 1018. A sampling volume 1024 containing the Sol-Gel 
Synchronous detection may be employed in the sensor of structure 200 of FIGS. 2, 3 or 4 occupies a section of the 
FIG. 1. For this purpose, a synchronous detection control 35 circular waveguide 1010. Light is coupled from the laser 
circuit 140 may control the pulse width and repetition rate of 1018 to the circular waveguide 1010 by evanescent cou- 
the laser l l 8  while enabling the detector 122 in synchronism pling, and light is coupled from the circular waveguide to the 
with the pulses of the laser 118. Alternatively, rather than photodetector by evanescent coupling between the circular 
pulsing the laser 118, the synchronous detection control and linear waveguides 1010,1030 at the contact point 1035. 
circuit 140 can dither one of the mirrors (e.g., the mirror 40 Thus, the photodetector 1022 ,receives a first light beam 
104) to pulse the light propagation in the ring interferometer. directly h m  the laser 1018 as well as a second (“shifted”) 
The synchronous detection control circuit 140 would enable light beam that has passed through the sampling volume 
the detector 122 in synchronism with the dithering of the 1024. The second light beam is phase shifted by an amount 
mirror so that the detector 122 is enabled with each pulse of depending upon the number of antigen-antibody bound pairs 
light. 45 in the sensing volume. Thus, the light intensity sensed by the 
FIG. 8 illustrates an integrated implementation of the photodetector 1022 is a function of the interference between 
sensor of FIG. 1 implemented on a substrate 800. The the two light beams in the same manner as described above 
substrate is formed of an optically tmnsparent material such with reference to the sensors of FIGS. 1 and 8. 
as glass or plastic or a semiconductor material or a ceramic. While the sensor has been described with reference to 
The optical paths 110, 112, 114, 116 of FIG. 1 are imple- 50 implementations in which an antibody for the targeted 
mented in FIG. 8 as a closed waveguide 801 having con- antigen is immobilized in the Sol-Gel structure, artificial 
nected sections 810, 812, 814, 816. The waveguide 801 is antibodies, Le., printed polymers, could be substituted for 
formed as a mesa or rib structure by etching the surface of the antibodies immobilized in the Sol-Gel. As another alter- 
the substrate 800 or by other methods well-known in the art. native, the sensor could be employed to sense or measure 
The cross-sectional height and width of the waveguide 801 55 other biological binding events, such as, for example, bind- 
may be selected by the skilled worker to support a single ing between a pair of complementary DNA strands. In this 
optical mode at the &equency of the laser 818. Mirrors 802, case, the Sol-Gel porous structure would be sized to immo- 
804,806,808 are placed at each corner between successive bilize single DN-4 strands. An analyte possibly containing 
waveguide sections 810, 812, 814, 816. A laser 818 is the complementary DNA strand would be introduced to the 
formed on the substrate 800 and feeds light into the 60 Sol-Gel. Complementary DNA strands would bind to the 
waveguide 801 through the back of the mirror 802. A immobilized DNA strands, thereby changing the refractive 
photodetector 822 is formed on the substrate 800 and index of the Sol-Gel. Thus, in general, the sensor detects 
receives light transmitted through the mirror 804. The mirror binding between complementary biological entities, one of 
804 performs the same function as the mirror 104 of FIG. 1, which is immobilized in the Sol-Gel and one of which is the 
in that it transmits a portion of the light in the waveguide 65 targeted entity to be detected. 
section 810 to the photodetector 822 while reflecting the While the invention ‘MS been described in detail by 
remaining portion to the next waveguide section 812. A specific reference to preferred embodiments, it is understood 
US 7,019,847 Bl 
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that variations and modifications thereof may be made 
without departing from the true spirit and scope of the 
invention. 
What is claimed is: 
1. A biosensor comprising: 
a sensing volume comprising an array of pores sized for 
immobilizing within said pores a first biological entity 
tending to bind to a second biological entity in such a 
manner as to change an index of refraction of said 
sensing volume; 
a ring interferometer, one volumetric section of said ring 
interferometer comprising said sensing volume; 
a laser for supplying light to said ring interferometer; 
a photodetector for receiving light from said interferom- 
2. The biosensor of claim 1 wherein said array of pores 
comprises nanometer-sized pores. 
3. The biosensor of claim 1 wherein said array of pores 
comprises Sol-Gel. 
4. The biosensor of claim 1 wherein said first biological 
entity comprises an antibody and said second biological 
entity comprises an antigen that binds to said antibody. 
5. The biosensor of claim 1 wherein said first biological 
entity comprises a printed polymer and said second biologi- 
cal entity comprises an antigen that binds to said printed 
polymer. 
6. The biosensor of claim 1 wherein said first biological 
entity comprises a first DNA or RNA strand and said second 
biological entity comprises a second DNA or RNA strand 
that is complementary to the first strand. 
7. The bios,ensor of claim 1 wherein said ring interfer- 
ometer comprises: 
a first optical path between said laser and said photode- 
tector, 
a second optical path that includes said one volumetric 
section comprising said sensing volume, said second 
optical path comprising a closed recirculating optical 
path, said second optical path being coupled to said first 
optical path whereby said first optical path receives 
light from said laser unaffected by said sensing volume 
and light that has passed through said sensing volume. 
8. The biosensor of claim 7 wherein said second optical 
path includes said first optical path. 
9. The biosensor of claim 7 wherein said second optical 
path is separate from said first optical path and is coupled to 
said first optical path by evanescent coupling. 
10. The biosensor of claim 1 further comprising a syn- 
c h r o ~ ~ ~  detection control circuit enabling said photodetec- 
tor in synchronism with a burst mode transmission of light 
in said ring interferometer. 
11. The biosensor of claim 7 wherein said first and second 
optical paths comprise respective waveguides. 
12. The biosensor of claim 11 wherein said respective 
waveguides are formed on a monolithic substrate, said 
respective waveguides comprising mesa rib structures on 
said substrate. 
13. The biosensor of claim 12 wherein said first optical 
path is along a straight line and said second optical path 
comprises a closed recirculating path. 
14. The biosensor of claim 13 wherein said closed path 
comprises plural straight paths defining a polygonal shape. 
15. The biosensor of claim 13 wherein said closed path 
lies along a circle. 
16. A biosensor comprising: 
a sensing volume comprising an m y  of pores sized for 
immobilizing within said pores a first biological entity 
eter. 
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tending to bind to a second biological entity in such a 
manner as to change an index of refraction of said 
sensing volume; 
units of said first biological entity immobilized in respec- 
tive ones of said pores; 
a ring interferometer, one volumetric section of said ring 
interferometer comprising said sensing volume; 
a laser for supplying light to said ring interferometer; 
a photodetector for receiving light fkom said interferom- 
17. The biosensor of claim 16 wherein said array of pores 
comprises nanometer-sized pores. 
18. The biosensor of claim 16 wherein said array of pores 
comprises Sol-Gel. 
19. The biosensor of claim 16 wherein said first biological 
entity comprises an antibody and said second biological 
entity comprises an antigen that binds to said antibody. 
20. The biosensor of claim 16 wherein said first biological 
20 entity comprises a printed polymer and said second biologi- 
cal entity comprises an antigen that binds to said printed 
polymer. 
21. The biosensor of claim 16 wherein said f3st biological 
entity comprises a fist  DN.4 strand and said second bio- 
25 logical entity comprises a second DNA strand that is 
complementary to said first DNA strand. 
22. The biosensor of claim 16 wherein said ring interfer- 
ometer comprises: 
a first optical path between said laser and said photode- 
a second optical path that includes said one volumetric 
section comprising said sensing volume, said second 
optical path comprising a closed recirculating optical 
pa% said second optical path being coupled to said first 
optical path whereby said first optical path receives 
light from said laser unaffected by said sensing volume 
and light that has passed through said sensing volume. 
23. The biosensor of claim 22 wherein said second optical 
24. The biosensor of claim 2 i  wherein said second optical 
path is separate from said first optical path and is coupled to 
said first optical path by evanescent coupling. 
25. The biosensor of claim 16 further comprising a 
45 synchronous detection control circuit enabling said photo- 
detector in synchronism with a burst mode transmission of 
light in said ring interferometer. 
26. The biosensor of claim 22 wherein said first and 
second optical paths comprise respective waveguides. 
27. The biosensor of claim 26 wherein said respective 
waveguides are formed on a monolithic substrate, said 
respective waveguides comprising mesa rib structures on 
said substrate. 
28. The biosensor of claim 27 wherein said first optical 
55 path is along a straight line and said second optical path 
comprises a closed recirculating path. 
29. The biosensor of claim 28 wherein said closed path 
comprises plural straight paths defining a polygonal shape. 
30. The biosensor of claim 24 wherein said closed path 
lies along a circle. 
31. The biosensor of claim 16 wherein said first biological 
entity comprises a first RNA strand and said second bio- 
logical entity comprises a second RNA strand that is 
5 
lo eter. 
30 tector; 
35 
4o path includes said first optical path. 
50 
6o 
65 complementary to said first RNA4 strand. 
* * * * *  
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